Clinical trials: Hepatitis B
Chronic Hepatitis B
A Study to Evaluate the Mass Balance Absorption and AME of VBR
This Phase 1 Study will determine the mass balance recovery, absorption, metabolism, and excretion of [14C] Vebicorvir in healthy male subjects
- Trial name
- NCT04637139
- Testing
- Vebicorvir (VBR)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
HIV Infections, Hepatitis B
Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders
The goal of this natural history study is to examine the immune responses to the Heplisav-B vaccine in Veterans living with HIV who were non-responders to prior HBV vaccination.
- Conditions
- HIV Infections, Hepatitis B, Vaccine Response Impaired
- Trial name
- HBR2 (NCT05791851)
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hepatitis B
Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths
This study will evaluate 2 licensed vaccine products (Recombivax and Twinrix) given in a two-dose schedule to youth at risk for hepatitis B and HIV infection to evaluate immunogenicity of the products in this population, barriers…
- Trial name
- NCT00107042
- Testing
- Recombivax, Twinrix
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Hepatitis b
IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB
The investigators observed the level of IL-35 secreting B regulatory (IL-35+Bregs) cells in peripheral blood cells in patients with chronic hepatitis B, and analysed the relationship between the IL-35+Bregs level and disease…
- Trial name
- NCT03734783
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Hepatitis B, Hepatitis A
Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule
The aim of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 6, 7, 8, 9 and 10 after subjects received their first two doses primary vaccination schedule of combined hepatitis…
- Trial name
- NCT00289744
- Testing
- TWINRIX™ ADULT, Engerix TM
- Where
- Belgium
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
Persistence of seroprotective antibody concentrations \& immunological memory shown by the ability to mount a response to a challenge dose of HBV vaccine
- Trial name
- NCT00356564
- Testing
- hepatitis B vaccine
- Where
- 42 sites in Germany
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B， Chronic
Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers
To evaluate the safety and tolerability of Hepalatide(L47) and characterize the clinical pharmacokinetics in healthy volunteers.
- Trial name
- NCT02612506
- Testing
- Hepalatide
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Chronic Hepatitis b
Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects
This is a single center, open-label, 3-Cohort, parallel, single-dose, study to evaluate the PK, safety, and tolerability of ATI-2173 50 mg administered orally in Japanese, Chinese, and Non-Asian healthy subjects incorporating a…
- Trial name
- NCT05298332
- Testing
- ATI-2173 50 mg
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Antios Therapeutics, Inc
Fibrosis, Liver
Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection
Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection
- Trial name
- NCT05567614
- Testing
- Liver Fibroscan
- Where
- Egypt
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Non-Hodgkin's Lymphoma
A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen
AIMS OF THE STUDY (STUDY OBJECTIVES) 1. To test the effect of daily lamivudine (100 mg) in reducing the risk of HBV reactivation and hepatitis development in HBsAg (+) NHL patients. 2.
- Trial name
- NCT00201318
- Testing
- Cyclophosphamide Doxorubicin Vincristine Lamivudine
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Chronic Hepatitis B
A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B
This three-part, Phase 1 protocol will be the first clinical study of ABI-H2158. Parts 1 and 2 will be a Phase 1a, dose-ranging assessment of ABI-H2158 in healthy adult volunteers.
- Trial name
- NCT03714152
- Testing
- ABI-H2158
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Hepatitis B
Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-HBV in healthy adult volunteers and participants with hepatitis B virus (HBV).
- Trial name
- NCT03365947
- Testing
- ARO-HBV, Sterile Normal Saline (0.9% NaCl), JNJ-56136379
- Where
- 7 sites in Australia, Hong Kong and 1 more
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Chronic HBV Infection
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
Part 1 is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-514 in healthy adult subjects.
- Trial name
- NCT04008004
- Testing
- EDP-514
- Where
- 15 sites in United States, Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Chronic Hepatitis B Virus Infection
A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.
Part 1 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EDP-721 in healthy subjects.
- Trial name
- NCT04971512
- Testing
- EDP-721, EDP-721 (Part 2), EDP-514
- Where
- New Zealand
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Chronic Hepatitis b
A Study of LP-128 Capsules in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LP-128 Capsules After Single- and Multiple-Dose in Healthy Subjects
- Trial name
- NCT05130567
- Testing
- LP-128 capsules
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Hepatitis B, Whole Cell Pertussis
Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib
This booster study will assess the immunogenicity, reactogenicity and safety of a booster dose of GSK Biologicals' DTPw-HBV/Hib Kft.
- Conditions
- Hepatitis B, Whole Cell Pertussis, Tetanus, Haemophilus Influenzae Type b
- Trial name
- NCT00332566
- Testing
- DTPw-HBV/Hib Kft vaccine GSK323527A, Tritanrix™-HepB/Hiberix™
- Where
- 2 sites in Argentina, Nicaragua
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants
This is an open-label study being done to compare two different methods of study medicine bepirovirsen is given in healthy adults.
- Trial name
- NCT07905157
- Testing
- Bepirovirsen
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Poliomyelitis
Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine
Pre-licensure studies of GSK Biologicals' PEDIARIX vaccine have shown it to be generally safe and unlikely to result in vaccine-associated serious adverse events.
- Conditions
- Hepatitis B, Poliomyelitis, Diphtheria, Tetanus
- Trial name
- NCT00146835
- Testing
- Pediarix, Licensed DTPa containing vaccine, Prevnar®: (Wyeth)
- Volunteers
- 120,794 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine
The aim of this Observer-blind study is to compare different Adjuvant Systems with the same, well-known antigen (HBsAg) already used in the GSK marketed vaccines against Hepatitis B (Engerix-BTM and FendrixTM), in order to better…
- Trial name
- NCT00805389
- Testing
- Engerix-B™, Fendrix™, GSK Biologicals' Hepatitis B vaccines (GSK223192A)
- Where
- 14 sites in Belgium, Germany
- Volunteers
- 713 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B Disease
Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)
This study was done to evaluate the effect of various adjuvants in combination with HBsAg as a model antigen on the induction of immune responses, mainly cytotoxic T lymphocytes (CTL) in healthy volunteers.
- Trial name
- NCT00508833
- Testing
- 287615 containing HBsAg with adjuvants
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline